Formulation of the next medium-term management plan
First written in FY2018. 12 of 19 entries say "Restated". Latest entry: 2026-09-17.
No other company in this theme has enough history to compare yet.
- 2026-09-17RestatedEarnings
「Under the medium-term management plan Make a Leap 2027, announced on 25 June 2025, our Group is promoting the PMI, or post-M&A integration process, of newly acquired companies and stores, strengthening the functions of family pharmacists and pharmacies, and working to strengthen its management base.」
The Company continues PMI, strengthening family pharmacist and pharmacy functions, and strengthening its management base under Make a Leap 2027. - FY2026AdvancedAnnual report
「The company positions the period covered by this medium-term plan as a foundation-building period, particularly to complete the PMI (M&A integration process) of companies and stores newly brought into the Group at an early stage, raise profit margins and operating efficiency, and achieve a further leap forward centred on the dispensing pharmacy business.」
In the first year of Make a Leap 2027, the company focused on executing post-M&A PMI and raising profit margins and operating efficiency. - FY2026-H1RestatedAnnual report
「(Dispensing pharmacy business) ① Strengthen the pharmacist's role as the patient's primary pharmacist ② Continue patient-centred pharmacy operations ③ Thoroughly implement initiatives to increase the number of prescriptions handled (Other) ④ Enhance M&A capabilities ⑤ Restructure existing businesses outside the dispensing pharmacy business ⑥ Promote sustainable corporate growth (sustainability)」
As its growth strategy under Make a Leap 2027, the company continues to pursue 6 initiatives covering dispensing pharmacies, M&A capabilities, restructuring of existing businesses and sustainability. - FY2025ReframedAnnual report
「In the medium-term management plan announced on 25 June 2025, Make a Leap 2027: Strengthen Our Foundation and Make a Further Leap Forward, the company newly defined its mission, vision and values,」
The company completed the previous LSG2024 plan and updated its medium-term management plan to Make a Leap 2027. It has reorganised the framework around a new growth strategy including post-M&A PMI, restructuring of existing businesses and sustainability. - FY2023RestatedAnnual report
「On 24 December 2021, the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024, and is pursuing (1) stronger initiatives to become a company chosen by investors, (2) stronger earnings generation through business expansion centred on the dispensing business, and (3) improvements to its earnings structure through further strengthening of its management foundation, with the aim of further increasing shareholder value and strengthening competitiveness to achieve growth.」
The company continues to pursue throughout the year the three areas of LSG2024, based on SFG2021. - FY2022AchievedAnnual report
「In the consolidated fiscal year, the company achieved its target management indicator for the final year of the plan, operating profit of ¥1.5 billion.」
In the fiscal year ending May 2022, the final year of SFG2021, the company achieved its operating profit target of ¥1.5 billion. It announced LSG2024 as its next plan and updated the planning framework. - FY2022-Q2ReframedAnnual report
「Against this backdrop, on 24 December 2021 the Group announced its medium-term management plan, LSG (Leading to Sustainable Growth) 2024. Based on the medium-term management plan SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth, announced on 8 November 2018 (hereinafter, the “current medium-term management plan”), the Group is pursuing (1) stronger initiatives to become a company chosen by investors, (2) stronger earnings generation through business expansion centred on the dispensing business, and (3) improvements to its earnings structure through further strengthening of its management foundation, with the aim of further increasing shareholder value and strengthening competitiveness to achieve growth.」
For the next medium-term management plan, the company announced LSG2024, based on the previous SFG2021, and reorganised the plan's framework around three areas: investors, the dispensing business, and the management foundation. - FY2022-Q1RestatedAnnual report
「Against this backdrop, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth, on 8 November 2018, and continues to pursue (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and a review of business methods and the Group's organisational structure. - FY2021RestatedAnnual report
「The company is targeting operating profit of ¥1.5 billion in the fiscal year ending May 2022, the final year of the plan.」
The company continues to target operating profit of ¥1.5 billion for the fiscal year ending May 2022, the final year of SFG2021. - FY2021-Q3RestatedAnnual report
「On 8 November 2018, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth (hereinafter, the “new medium-term management plan”), and continues to pursue (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and business methods and the Group's organisational structure. - FY2021-Q2RestatedAnnual report
「Against this backdrop, on 8 November 2018 the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth (hereinafter, the “new medium-term management plan”), and continues to pursue (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and a review of business methods and organisational structure. - FY2020AdvancedAnnual report
「The company is targeting operating profit of ¥1.5 billion in the fiscal year ending May 2022, the final year of the plan.」
The company specified a final-year target of ¥1.5 billion in operating profit for SFG2021 in the fiscal year ending May 2022. - FY2020-Q2RestatedAnnual report
「On 8 November 2018, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth (hereinafter, the “new medium-term management plan”), and is pursuing (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and business methods and the Group's organisational structure. - FY2020-Q1RestatedAnnual report
「On 8 November 2018, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth (hereinafter, the “new medium-term management plan”), and is pursuing (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and business methods and the Group's organisational structure. - FY2019-Q3RestatedAnnual report
「On 8 November 2018, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth, and is pursuing (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The company continues to pursue the three areas of SFG2021: dispensing pharmacies, retail, and business methods and organisational structure. - FY2019-Q2AdvancedAnnual report
「On 8 November 2018, the Group announced its medium-term management plan, SFG (Steps for Future Growth) 2021: Building a Management Foundation for Growth, and is pursuing (1) stronger competitiveness in the dispensing pharmacy business, new store openings and accelerated M&A, (2) expansion of the retail business and improved profitability, and (3) improvements to its earnings structure through a review of business methods and the Group's organisational structure.」
The next medium-term management plan, which was under preparation, was announced as SFG2021 on 8 November 2018. It identified three specific areas for implementation: dispensing pharmacies, retail, and business methods and organisational structure. - FY2018First statedAnnual report
「The direction of this management strategy is not expected to change significantly, and the company is currently preparing its next medium-term management plan.」
The company stated for the first time that it was preparing its next medium-term management plan without materially changing its current strategic direction.